Book a demo
Skip to content

Stonewake Monitoring

Moderna, Inc. files 8-K covering a new debt obligation

The biotechnology company disclosed a debt obligation in an 8-K filed with the SEC on September 1, 2026.

Export financeUSAPublished · 3 sourced facts

Moderna, Inc., a Delaware-incorporated biological products company traded on Nasdaq under the ticker MRNA, filed an 8-K with the SEC on September 1, 2026.[1][2]

The filing, dated for a period ending August 27, 2026, covers a debt obligation and reports items 1.01, 2.03, 3.02, 8.01, and 9.01.[1]

The submission carries accession number 0001193125-26-378505 and its matched document is d108896d8k.htm.[1]

The company had previously disclosed an executive departure in a filing dated July 8, 2026.[3]

Sources

  1. [1]SEC EDGAR: 8-K, 0001193125-26-378505, 1 Sep 2026
  2. [2]SEC EDGAR: CIK 0001682852, Moderna, Inc.
  3. [3]SEC EDGAR

SEC EDGAR

← All briefs